Literature DB >> 12672400

Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy.

Ping Ye1, Athena P Kourtis, Denise E Kirschner.   

Abstract

The extent to which highly active antiretroviral therapy can restore thymic function in HIV-1 infected patients is not known. We simulate treatment using a temporal model of thymopoiesis during HIV-1 infection, tracking thymic function by the number of recent thymic emigrants (RTE) exported to the periphery per day. Our results suggest that suppressing viral load in peripheral blood and improving inherent thymic function are necessary for the reconstitution of RTE levels in adult thymic infection with either R5 or X4 HIV-1 strains. This is also the case in pediatric thymic infection with R5 strains. However, recovery of RTE levels during pediatric infection with X4 strains also depends on high drug efficacy within the thymus. We further predict that protease inhibitors have high levels of efficacy directly suppressing viral replication within the thymus, while reverse transcriptase inhibitors have low efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672400     DOI: 10.1016/s1521-6616(02)00024-4

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

Review 1.  Thymic function in HIV infection.

Authors:  Rohan Hazra; Crystal Mackall
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

2.  Homeostasis of the naive CD4+ T cell compartment during aging.

Authors:  Ryan D Kilpatrick; Tammy Rickabaugh; Lance E Hultin; Patricia Hultin; Mary Ann Hausner; Roger Detels; John Phair; Beth D Jamieson
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

3.  A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Authors:  Jeffrey M Jacobson; Hongying Wang; Rebeka Bordi; Lu Zheng; Barry H Gross; Alan L Landay; John Spritzler; Jean-Pierre Routy; Constance Benson; Judith Aberg; Pablo Tebas; David W Haas; Jennifer Tiu; Kristine Coughlin; Lynette Purdue; Rafick-Pierre Sekaly
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

4.  Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.

Authors:  Sher L Hendrickson; Lisa P Jacobson; George W Nelson; John P Phair; James Lautenberger; Randall C Johnson; Lawrence Kingsley; Joseph B Margolick; Roger Detels; James J Goedert; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

5.  Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection.

Authors:  Mercedes Márquez; Paula Romero-Cores; Monserrat Montes-Oca; Andrés Martín-Aspas; María-José Soto-Cárdenas; Francisca Guerrero; Clotilde Fernández-Gutiérrez; José-Antonio Girón-González
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.